Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos

39 Background: The VISION trial showed that 177Lu-PSMA can prolong survival and improve the quality of life of patients with advanced mCRPC. The VISION trial used PSMA-PET/CT to select patients for inclusion. Here, we evaluated the outcome of patients treated with 177Lu-PSMA who would have been screen failure (SF) by VISION-PET criteria. Methods: We conducted a retrospective cohort study in our...

  • 123456 Profile photo of Madelyn

    ASCO GU 2022: Patients who had disease that failed screening (ie not eligible for the vision trial based on PSMA-PET/CT criteria) had worse outcomes with 177Lu-PSMA treatment. When considering referring patients for 177Lu-PSMA, it is important to consider the imaging inclusion criteria.